Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Boehringer Ingelheim
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Seagen Inc.
Fate Therapeutics
Seagen Inc.
Seagen Inc.
UNICANCER
Cancer Research UK
Enliven Therapeutics
Suzhou Teligene Ltd.
Seagen Inc.
Academic and Community Cancer Research United
Hoffmann-La Roche
Fate Therapeutics
Oslo University Hospital
Silverback Therapeutics
NSABP Foundation Inc
Fudan University
Fate Therapeutics
Second Affiliated Hospital, School of Medicine, Zhejiang University
NKGen Biotech, Inc.
Western Regional Medical Center
Peking University
Shanghai Changzheng Hospital
Fondazione del Piemonte per l'Oncologia
National Cancer Institute (NCI)
National Cancer Institute (NCI)